Sphingolipids in Alzheimer's disease, how can we target them?
| Jazyk: | angličtina |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
GW4869
BLOOD-BRAIN-BARRIER CERAMIDE SYNTHASE 2 NERVE GROWTH-FACTOR Alzheimer's disease MITOCHONDRIAL OUTER-MEMBRANE Fingolimod (FTY720) Tricyclic dibenzoazepines (TCA) ANTIGEN-BINDING PROTEIN Ceramide AMYLOID PRECURSOR PROTEIN Sphingomyelin (SM) KINASE-C-ZETA Blood brain barrier (BBB) SERINE PALMITOYLTRANSFERASE INHIBITOR CULTURED HIPPOCAMPAL-NEURONS P75 NEUROTROPHIN RECEPTOR Sphingosine-1-phosphate (S1P) |
| Zdroj: | Advanced Drug Delivery Reviews. 159:214-231 |
| ISSN: | 0169-409X |
| Popis: | Altered levels of sphingolipids and their metabolites in the brain, and the related downstream effects on neuronal homeostasis and the immune system, provide a framework for understanding mechanisms in neurodegenerative disorders and for developing new intervention strategies. In this review we will discuss: the metabolites of sphingolipids that function as second messengers; and functional aberrations of the pathway resulting in Alzheimer's disease (AD) pathophysiology. Focusing on the central product of the sphingolipid pathway ceramide, we describ approaches to pharmacologically decrease ceramide levels in the brain and we argue on how the sphingolipid pathway may represent a new framework for developing novel intervention strategies in AD. We also highlight the possible use of clinical and non-clinical drugs to modulate the sphingolipid pathway and sphingolipid-related biological cascades. (C) 2020 Elsevier B.V. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect